Tang Jinxin, Zhang Jinhui, Lu Yu, He Jieyu, Wang Hua, Liu Binfeng, Tu Chao, Li Zhihong
Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Biomark Res. 2023 Apr 17;11(1):42. doi: 10.1186/s40364-023-00484-7.
N6-methyladenosine (mA) is considered as the most common and important internal transcript modification in several diseases like type 2 diabetes, schizophrenia and especially cancer. As a main target of mA methylation, long non-coding RNAs (lncRNAs) have been proved to regulate cellular processes at various levels, including epigenetic modification, transcriptional, post-transcriptional, translational and post-translational regulation. Recently, accumulating evidence suggests that mA-modified lncRNAs greatly participate in the tumorigenesis of cancers. In this review, we systematically summarized the biogenesis of mA-modified lncRNAs and the identified mA-lncRNAs in a variety of cancers, as well as their potential diagnostic and therapeutic applications as biomarkers and therapeutic targets, hoping to shed light on the novel strategies for cancer treatment.
N6-甲基腺嘌呤（mA）被认为是2型糖尿病、精神分裂症尤其是癌症等多种疾病中最常见且最重要的内部转录修饰。作为mA甲基化的主要靶点，长链非编码RNA（lncRNA）已被证明在多个层面调控细胞过程，包括表观遗传修饰、转录、转录后、翻译及翻译后调控。最近，越来越多的证据表明，mA修饰的lncRNA在癌症的肿瘤发生过程中发挥着重要作用。在本综述中，我们系统总结了mA修饰的lncRNA的生物合成过程、在多种癌症中已鉴定出的mA-lncRNA，以及它们作为生物标志物和治疗靶点在潜在诊断和治疗方面的应用，希望能为癌症治疗的新策略提供思路。
